178 related articles for article (PubMed ID: 26940442)
1. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
3. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.
Markelewicz RJ; Lorenzen WA; Shusterman S; Grant FD; Fahey FH; Treves ST
Clin Nucl Med; 2013 Aug; 38(8):604-7. PubMed ID: 23797228
[TBL] [Abstract][Full Text] [Related]
4. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
6. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
Pandit-Taskar N; Zanzonico P; Hilden P; Ostrovnaya I; Carrasquillo JA; Modak S
Clin Nucl Med; 2017 Oct; 42(10):741-748. PubMed ID: 28759518
[TBL] [Abstract][Full Text] [Related]
8. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of
Sevrin F; Kolesnikov-Gauthier H; Cougnenc O; Bogart E; Schleiermacher G; Courbon F; Gambart M; Giraudet AL; Corradini N; Badel JN; Rault E; Oudoux A; Deley MCL; Valteau-Couanet D; Defachelles AS
Pediatr Blood Cancer; 2023 Nov; 70(11):e30615. PubMed ID: 37574821
[TBL] [Abstract][Full Text] [Related]
10. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
11. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
George SL; Falzone N; Chittenden S; Kirk SJ; Lancaster D; Vaidya SJ; Mandeville H; Saran F; Pearson AD; Du Y; Meller ST; Denis-Bacelar AM; Flux GD
Nucl Med Commun; 2016 May; 37(5):466-72. PubMed ID: 26813989
[TBL] [Abstract][Full Text] [Related]
12. Radiation exposure in nurses during care of
Taniguchi Y; Wakabayashi H; Inaki A; Kayano D; Yamada M; Kinuya S
Ann Nucl Med; 2020 Jun; 34(6):441-447. PubMed ID: 32297135
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.
Lashford LS; Lewis IJ; Fielding SL; Flower MA; Meller S; Kemshead JT; Ackery D
J Clin Oncol; 1992 Dec; 10(12):1889-96. PubMed ID: 1453204
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma
Chimeno JM; Sebastià N; Torres-Espallardo I; Balaguer J; Candela-Juan C; Loaiza JL; Adria M; Ibanez-Rosello B; Cañete A; Martí-Bonmatí L; Montoro A
Int J Radiat Biol; 2019 Mar; 95(3):314-320. PubMed ID: 30496023
[TBL] [Abstract][Full Text] [Related]
15. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
16. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.
Klingebiel T; Treuner J; Ehninger G; Keller KD; Dopfer R; Feine U; Niethammer D
Cancer Chemother Pharmacol; 1989; 25(2):143-8. PubMed ID: 2598401
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience.
Shusterman S; Grant FD; Lorenzen W; Davis RT; Laffin S; Drubach LA; Fahey FH; Treves ST
Semin Nucl Med; 2011 Sep; 41(5):354-63. PubMed ID: 21803185
[TBL] [Abstract][Full Text] [Related]
18. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
Flower MA; Fielding SL
Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
[TBL] [Abstract][Full Text] [Related]
19. Reaching the target dose with one single
Fiz F; Cirone A; Righi S; Massollo M; Amoroso L; Bottoni G; Conte M; Gambaro M; Massone F; Orengo S; Bruzzone GS; Sorrentino S; Garaventa A; Piccardo A
Pediatr Blood Cancer; 2024 Mar; 71(3):e30806. PubMed ID: 38082548
[TBL] [Abstract][Full Text] [Related]
20. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]